ENTITY

argenx (ARGX BB)

1
Analysis
Health Care • Netherlands
argenx is a global immunology company focused on developing and commercializing antibody-based medicines for severe autoimmune diseases. Its flagship product, VYVGART (efgartigimod), is approved for generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is headquartered in Amsterdam, the Netherlands, and was founded in 2008.
more
Company Event • 25 Feb 2027 19:00 • Upcoming
Add To Calendar

Q4 2026

Company Event • 14 Sep 2026 21:15 • Latest

Morgan Stanley 24th Annual Global Healthcare Conference

Company Event • 08 Sep 2026 21:30

Wells Fargo 21st Annual Healthcare Conference

Company Event • 17 Aug 2026 20:30

Study update

Company Event • 27 Jul 2026 20:00

M&A announcement

x